XAF-1 exists as a single gene with eight exons, which localizes to chromosome 17p13.2, a region just telomeric to the p53 gene. 1 Although XAF-1 has been shown to have a potent proapoptotic activity and to act as a tumor suppressor in several solid tumors by inhibiting X-linked inhibitor of apoptosis at the mitochondrial level, 2 its potential role in hematological malignancies has not been addressed. As 17p-deletion has been associated with poor prognosis in patients affected by B chronic lymphocytic leukemia (B-CLL), 3 we have analyzed the steady-state messenger RNA (mRNA) levels of XAF-1 in a cohort of B-CLL samples, characterized for CLL-associated chromosomal aberrations using fluorescence in situ hybridization (FISH), Zap70 levels and p53 status (Table 1) . Fifteen patient samples showed a monoallelic p53 deletion associated to 17pÀ (p53 deleted). Five patient samples with 17pÀ also carried the p53 mutation (p53 mutated) in the remaining allele (patients 11-12; 14-16 of Table 1 ), while one patient sample showed p53 mutation without detectable defects on 17p at FISH analysis (patient 10 of Table 1 ). When assayed ex vivo for cytotoxic response to 10 mM of the non-genotoxic activator of the p53 pathway Nutlin-3, 4 B-CLL samples showed a variable susceptibility to Nutlin-3 cytotoxicity upon 48 h of treatment (Table 1 del/mut (median cell viability of 69%, mean ± s.d.: 69.3 þ 13.8). In order to compare the levels of expression of XAF-1 in these two groups, the amount of mRNA was assessed using the real-time thermal analyzer RotorGeneTM 6000 (Corbett, Cambridge, UK) by using SYBR Green based-technology and the reverse transcriptase-polymerase chain reaction primer sets specific for the indicated human cDNA (SABioscience, Frederick, MD, USA). The steady-state XAF-1 mRNA levels were significantly (Po0.05) lower in p53 del/mut (median: 2.6, mean þ s. . As these data suggested that increased levels of XAF-1 expression might have an important role in sensitizing leukemic cells to Nutlin-3-mediated apoptosis, in the last group of experiments XAF-1 expression was attenuated using a small interfering RNA (siRNA) transfection approach. For this purpose, SKW6.4 cells (1.25 Â 10 6 ) were resuspended into 0.1 ml of Nucleofector solution V of the human nucleofector kit V (Amaxa, Cologne, Germany). A pool of three target-specific 20-25 nt siRNAs (human XAF1 siRNA), as well as a cocktail of three different negative control siRNAs (control siRNA), each comprising a 20-25-nt scrambled sequence that will not lead to the specific degradation of any known cellular mRNA, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The efficiency and specificity of the XAF-1 knockdown were documented in preliminary experiments by a significant decrease of the steady-state mRNA XAF-1 levels in SKW6.4 cells transfected with siRNA for XAF-1 but not in cells transfected with control scrambled siRNA (data not shown). Of note, in SKW6.4 samples in which XAF-1 expression was knocked down by transfection with XAF-1-specific siRNAs, the cytotoxicity of Nutlin-3 plus IFN-b was significantly (Po0.05) lower with respect to either cells transfected with a scrambled control siRNA or cells not transfected ( Figure 1d ).
Our data suggest that XAF-1 might represent an important determinant in modulating the cytotoxic activity of Nutlin-3 and probably also of other pro-apoptotic drugs in B-CLL cells. In fact, p53 del/mut B-CLL samples, which are less responsive to chemotherapeutic or Nutlin-3 treatment than p53 wt B-CLL samples, showed low levels of XAF-1 mRNA. Moreover, modulating the steady-state mRNA levels of XAF-1 through IFN-b treatment or silencing the XAF-1 gene significantly affected the Nutlin-3-mediated cytotoxicity in selected samples of primary p53 wt and p53 del/mut B-CLL as well as in leukemic cell lines. Our current findings are interesting also in light of previous data showing that XAF-1 is a natural antagonist of the inhibitor of apoptosis family proteins, 2 which are believed to contribute to cancer progression and to decrease the sensitivity to drug and radiation therapy. In a recent study, Steele et al. 7 showed that the transcriptional blockade of p53 through pifithrin-a (PFTa) increases the Nutlin-3 ability to induce apoptosis facilitating the translocation of p53 to mitochondria. Thus, future studies should be aimed at evaluating whether permissive levels of XAF-1 are necessary for an optimal p53-mediated cytotoxic activity at the mitochondrial level. It Percentage of viability was measured at 48 h of treatment with 10 mM of Nutlin-3.
Letters to the Editor is also noteworthy that another study has shown that PFTa not only abrogates the p53 transcriptional activity, but also induces the transcriptional activity of XAF-1 expression, 8 further suggesting that XAF-1 levels are an important determinant in the cytotoxic activity of p53. In conclusion, although Nutlin-3 has still not been tested in vivo in B-CLL, drugs able to increase the levels of XAF-1 should be further considered for future therapeutic combinations in the treatment of B-CLL with either Nutlin-3 or other chemotherapeutic drugs that are able to activate the p53 pathway, such as fludarabine.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
This study was supported by grants from the Italian Association for Cancer Research (AIRC) and Beneficientia Foundation (both to GZ). 
Letters to the Editor
Interestingly, among the 12 cases showing A20 deletion, 3 displayed a homozygous deletion, indicating complete inactivation of the gene. While preparing our manuscript, four independent studies reported biallelic inactivation of A20 by mutation and/or deletion in 67/381 (17.5%) B-cell lymphomas, including MALT lymphoma, diffuse large B-cell lymphoma and Hodgkin lymphoma.
3-6 A20, also known as TNF a-induced protein 3 (TNFAIP3), is a well-known negative regulator of the NF-kB activation pathway and can attenuate the NF-kB activity triggered by signaling from TNF and Toll-like receptors. 7 In view of these findings, A20 could potentially act as a tumor suppressor gene. Nonetheless, it remains to be investigated whether A20, like other tumor suppressor genes, is also targeted for inactivation by promoter methylation and whether A20 abnormalities impact on clinical presentation and treatment response. In this study, we investigated A20 genetic and epigenetic abnormalities, and also examined the clinical impact of A20 inactivation in MALT lymphoma.
A total of 17 MALT lymphomas with available adequate DNA samples or tissue materials were screened for mutation in the A20 coding sequence by PCR and sequencing using DNA samples extracted from microdissected tumor cells of formalin-fixed paraffin-embedded tissue biopsies (Supplementary Materials and methods; Supplementary Table S1). They included seven cases showing A20 hemizygous deletion with or without TNF locus gain, four cases with TNF locus gain only and a further six cases without these abnormalities. 2 A total of 4 mutations were detected in 3 (17.6%) of the 17 cases examined. All the mutations were confirmed by sequencing at least two independent PCR products from both orientations and excluded from the known polymorphisms. Cases 9 and 12 showed one nonsense mutation each, whereas case 16 showed one nonsense mutation and a 2 bp deletion (frozen tissue was not available, thus not possible to further investigate whether these mutations occurred in one or both alleles) ( Table 1) . Case 9 showed both A20 mutation and hemizygous deletion, whereas cases 12 and 16 showed A20 gene mutation but not deletion.
A20 promoter methylation was investigated in a total of 27 MALT lymphomas of the ocular adnexa (25), salivary glands (1) and thyroid (1) (Supplementary Materials and methods) . Genomic DNA was treated by bisulfite to convert unmethylated cytosine to uracil, while keeping methylated cytosines intact, and then analyzed by pyrosequencing to assess methylation of 18 consecutive CpG positions in the A20 promoter region. High efficiency of bisulfite treatment was demonstrated by internal conversion controls (Figure 1 ). The reliability of the assay was further ascertained by reproducible results from independent bisulfite treatments and pyrosequencing experiments. A20 promoter methylation was seen in 7 (26%) of the 27 MALT lymphomas investigated, and they included 5 ocular adnexal cases and both extra-ocular cases (Table 1; Figure 1 ). Of these seven cases, six showed a similar methylation pattern, with prominent methylation at the 7th, 8th and 9th CpG sites. Remarkably, A20 promoter methylation was significantly associated with A20 hemizygous deletion (P ¼ 0.011, Fisher's exact test), being found in 5/8 (62%) cases with hemizygous deletion, but only in 2/19 (11%) cases with an intact A20 ( Table 1) . None of the four cases with A20 promoter methylation, which were also investigated for mutation, showed A20 gene mutation. The single case (no. 9) that harbored both A20 gene deletion and nonsense mutation showed no evidence of A20 promoter methylation. Thus, it appeared that A20 promoter methylation and gene mutation are mutually exclusive. To our knowledge, this is the first comprehensive analysis
